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Abstract
Purpose: Head and neck tumours include tumours of nose, paranasal sinuses, oropharynx, larynx and mouth. 
Squamous cell carcinoma (SCC) is the most common head and neck malignant tumour which accounts for 90% of 
head and neck malignant tumours. p21 is an important immunohistochemical marker which has significant role in 
predicting prognosis of head and neck SCC (HNSCC). Increased p21 expression in HNSCC is associated with bad 
prognosis in terms of increased risk of nodal metastasis, increased rate of recurrence and decreased survival rate. The 
purpose of this study was to evaluate the expression of p21 in HNSCC with various clinicopathologic and prognostic 
parametres.
Materials and Methods: A total of 110 patients (n = 110) of HNSCC (oral cavity n = 98 and laryngeal tumours 
n = 12) were included in the study which were diagnosed and treated between January 2008 and January 2011 at 
a tertiary care centre in Pakistan. Mean age was 51 years (age range 15–78). 65 (59%) were male and 45 (41%) 
were female. Tumours were classified as p21 positive when ≥10% tumour cells were immunoreactive for p21. p21 
expression was noted and correlated with T-stage, nodal metastasis, perineural and depth of invasion, recurrence and 
2-year survival rate.
Results: Of 110 cases, p21-positive cases were 88 (80%) compared to 22 (20%) negative. T1–T2 tumours with p21 
expression were 59 (67.04%) while 17 cases (77.27%) had negative for p21 (P = 0.44). Amongst T3–T4, 29 cases 
showed p21 expression (32.96%) while 5 cases (22.73%) were negative (P = 0.44). Nodal metastasis was seen 
in 51 cases (57.95%) with p21 positivity as compared to 4 cases (18.8%) with no p21 expression (P = 0.0015). 
Perineural invasion was seen in 15 carcinomas (17.04%) having p21 positivity and 1 case (4.54%) with p21 negativity 
(P = 0.18). 48 cases (54.54%) had depth of invasion >1 cm with positive p21 as compared to 4 cases (18.18%) without 
(P value = 0.0035). 39 cases (44.31%) showed recurrence along with p21 expression while 3 cases (13.63%) showed 
recurrence without (P = 0.0076). 2-year survival rate was 56.81% (n = 88) in p21-positive cases, whereas it was 
90.90% (n = 20) those with negative p21 (P = 0.0026).
Conclusion: Positive p21 expression in HNSCC correlates with intermediate grade, late stage, increased nodal 
metastasis, tumour recurrence and decreased survival. p21 should be considered as an important prognostic and 
predictive marker in HNSCC to detect tumours at early stage and to improve therapy and prognosis.
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Introduction
Head and neck tumours include tumours of nose, paranasal 
sinuses, oropharynx, larynx and mouth.[1] Squamous cell 
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carcinoma (SCC) is the most common head and neck 
malignant tumour which accounts for 90% of head and 
neck malignant tumours.[2] Etiological factors include 
tobacco smoking, alcohol intake, betel nut chewing, 
ultraviolet light, certain occupational chemicals and few 
viruses like human papilloma virus.[3]
In recent years, certain risk factors such as betel nut 
chewing and use of smokeless tobacco (snuff) have led to 
increased incidence of head and neck SCC (HNSCC).[4] 
HNSCC diagnosed on biopsies is treated by surgery, 
radiation therapy, chemotherapy, targeted therapy or 
combination of treatments. Failure of treatment in HNSCC 
is most likely due to local and regional recurrence. Lymph 
node metastasis leads to poor prognosis and decreased 
survival rate.[5] Head and neck cancers include many 
other types, but SCC is most common and most frequent 
malignant tumour in this region. Multiple steps are 
involved in carcinogenesis of HNSCC including activation 
and suppression of tumour suppressor genes. Cell cycle 
balance is disturbed and uncontrolled cell growth starts 
as compared to cell death.
Many cell cycle regulators such as cyclins, cyclin-
dependent kinases (CDKS), oncogenes and tumour 
suppressor genes play an important role in maintaining 
cell cycle and regulating balance between cell growth 
and cell death.
p21 is a new-emerging immunohistochemical marker 
which has significant role in predicting prognosis 
of HNSCC. Increased p21 expression in HNSCC is 
associated with worse prognosis in terms of increased 
risk for nodal metastases, increased rate of recurrence 
and decreased survival rate. p21 is a CDKS inhibitor and 
plays a significant role in various steps of cell cycle and 
tumour cell death.[6]
The purpose of this study was to determine the expression 
of p21 in HNSCC with various clinicopathologic and 
prognostic parametres.
Materials and Methods
A total of 110 patients (n = 110) of NSCC were included 
in the study which were diagnosed and treated between 
January 2008 and January 2011 at a tertiary care centre 
in Pakistan. Of 110 cases, 63 were from tongue, 16 from 
buccal mucosa, 4 from lip, 15 from alveolar mucosa and 
12 from larynx. Mean age was 51 years (age range 15–78). 
65 (59%) were male and 45 (41%) were female. Tumours 
were classified as p21 positive when ≥10% tumour cells 
were immunoreactive for p21. Cutoff scores for p21 
were determined by receiver operating characteristic 
curve analysis that is a cut point determination method.[5] 
Nuclear positivity of p21 in HNSCC was noted, intensity 
of staining was not taken into consideration. p21 
expression was noted and correlated with T-stage, nodal 
metastasis, perineural and depth of invasion, recurrence 
and 2-year survival rate.
Results
Of 110 cases, p21-positive cases were 88 (80%) compared 
to 22 (20%) negative. T1–T2 tumours with p21 expression 
were 59 (67.04%) while 17 cases (77.27%) had negative 
for p21 (P = 0.44). Amongst T3–T4, 29 cases showed 
p21 expression (32.96%) while 5 cases (22.73%) were 
negative (P = 0.44). Nodal metastasis was seen in 51 cases 
(57.95%) with p21 positivity as compared to 4 cases 
(18.8%) with no p21 expression (P = 0.0015). Perineural 
invasion was seen in 15 carcinomas (17.04%) having 
p21 positivity and 1 case (4.54%) with p21 negativity 
(P = 0.18). 48 cases (54.54%) had depth of invasion >1 cm 
with positive p21 as compared to 4 cases (18.18%) without 
p21 (P = 0.0035). 39 cases (44.31%) showed recurrence 
along with p21 expression while 3 cases (13.63%) showed 
recurrence without p21 (P = 0.0076). 2-year survival rate 
was 56.81% (n = 88) in p21-positive cases, whereas it was 
90.90% (n = 20) those with negative p21 (P = 0.0026).
Discussion
As part of cell cycle, p21 is an important cell cycle 
regulator such as p53 and p16. p21 binds to CDKS. 
Since cyclins inhibit apoptosis, it is thus a key factor in 
regulating the cell cycle at G1 phase.[7]
Cyclin D/Cdk4 complex activated by p21, plays a 
major role in cell cycle.[8] Cdk4-cyclin D interaction is 
controlled by p21 which forms complexes.[9] p21 along 
with other regulators, such as p27 and survivin, controls 
apoptosis.[10,11] p21 is an antiapoptotic factor and by 
inhibiting apoptosis interacts with normal cell cycle 
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progression.[12] p21 also plays a role in cell cycle along 
with p53 which is also an important part of cell cycle.[13]










T1–T2 59 (67.04) 17 (77.27) 0.44
T3–T4 29 (32.96) 5 (22.73)
Nodal metastasis 51 (57.95) 4 (18.8) 0.0015
Tumour grade
G1–G2 79 (89.77) 19 (86.36) 0.70
G3 9 (10.23) 3 (13.64)
Depth of invasion
<1 cm 40 (45.46) 18 (81.82) 0.0035
>1 cm 48 (54.54) 4 (18.18)
Perineural 
invasion
15 (17.04) 1 (4.54) 0.18
Recurrence 39 (44.31) 3 (13.63) 0.0076
2‑year survival 
rate
56.81 (n=88) 90.90 (n=22) 0.0026
Kaplan–Meier survival curve demonstrates 2-year 
survival rate of patients with p21-positive and negative 
expression.
Our study aimed at depicting antiapoptotic effect of p21 
in HNSCC, to predict prognosis. Possible mechanism 
for the role of p21 role in predicting prognosis includes 
its proliferative effect in tumour and surrounding cells. 
Our study correlated with worse prognosis with positive 
p21 expression in HNSCC when compared with negative 
expression.
In our study, p21 clearly led to a higher incidence of nodal 
metastasis 57.95% compared with 18.8% in p21-negative 
carcinomas. Locoregional relapse was also high with p21-
positive HNSCC as compared to p21-negative tumours 
(44.31% vs. 13.63%). 2-year survival rate was low with 
p21-positive carcinomas (56.81%) as compared to p21 
negative (90.90%). A study showed that expression of 
this marker leads to increased lymph node metastases, 
recurrence and decreased survival rate, hence, predicting 
poor prognosis [Figures 1-5]. Figure 3: p21 staining (positive), ×20
Figure 2: Squamous cell carcinoma, ×20, H and E stain
Figure 1: Survival functions
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In a study by Fischer et al. in which p21 expression 
was evaluated in 117 HNSCC and Ki67 expression in 
116 cases, increased p21 expression led to increased nodal 
metastases, tumour recurrence and decreased survival 
rate. In their retrospective study with 117 patients of 
HNSCC, lymph node metastases were seen in 93.7% 
with p21-positive carcinomas and 66.7% with p21-
negative tumours. In the same study, 5-year survival 
rate was 35.2% with positive p21 expression and 54.7% 
with negative expression, thus they confirmed decreased 
overall survival rate with positive p21 expression. They 
also showed 24.3% 5-year survival rate with Ki67 
expression and 50.2% in that negative Ki67 expression, 
(Ki67 was considered positive when ≥60% tumour cells 
were immunoreactive for Ki67), thus having similar result 
like that for p21. In addition, coexpression of both p21 
and ki67 showed worse prognosis with increased nodal 
metastases, recurrence and decreased survival rate.[5]
In another study by Fizazi et al.[16] related to p21 and 
Ki67 expression in prostatic cancer, it was concluded 
that p21 is an important prognostic and predictive marker 
of tumour recurrence and survival along with increased 
Ki67 expression.
Similar results were observed in the study by Lavertu 
et al., they proposed regular follow-up of patients 
with increased expression of these markers to decrease 
recurrence, detect second primary at earlier stage and 
improve survival.[17]
In our study, p21 positivity was observed in 80% of 
cases. This frequency of p21-positive HNSCC positively 
correlates with many studies, which showed frequency 
ranging from 58% to 82%.[18-21]
The possible major mechanism of action for p21 in 
HNSCC includes its antiapoptotic effect,[14] uncontrolled 
cellular proliferation and decreased cell death, hence, 
p21 reducing survival rate by developing resistance to 
therapy.[15,22]
Conclusion
Positive p21 expression in HNSCC correlates with 
increased nodal metastases, tumour recurrence and 
decreased survival. p21 is an important prognostic and 
predictive marker in HNSCC. Its expression should be 
evaluated to detect tumours at early stage, to improve 
therapy and prognosis.
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